British Pharmacopoeia (BP) 2027

British Pharmacopoeia 2027 Hard Copy (Printed) Edition

The British Pharmacopoeia 2027 (BP 2027) is the UK’s legally enforceable compendium of pharmaceutical standards, essential for ensuring compliance in medicine development, manufacture, and testing. Effective from 1 January 2027, BP 2027 replaces BP 2026.

Updated annually, the British Pharmacopoeia (BP) is the only comprehensive collection of authoritative official standards for UK pharmaceutical substances and medicinal products. It includes approximately 4,000 monographs, which are legally enforced by the Human Medicines Regulations 2012. Medicinal products or active pharmaceutical ingredients sold or supplied in the UK must comply with the relevant monograph.

What’s new for BP 2027?

• The BP 2027 print edition includes European Pharmacopoeia content up to Issue 12.3.
• One new infrared reference spectrum has been added to the collection.
• 13 new BPCRS
• 132 amended BP texts

Why BP 2027 matters
The British Pharmacopoeia is the only government-sanctioned pharmaceutical compendium in the UK, carrying full legal authority under the Human Medicines Regulations. BP 2027 ensures that all pharmaceutical substances and products meet current UK and EU quality standards. Trusted worldwide, BP is used in over 100 countries, supporting global compliance and harmonised pharmaceutical practices.

Format and Features
This six-volume BP 2027 printed edition delivers durability, clarity, and offline access to the most up-to-date pharmaceutical standards. Each volume is professionally bound for laboratory, regulatory, or library use. The print set remains an essential reference for professionals who require reliable, quick, and uninterrupted access to official standards.

Who should use BP 2027

• Pharmaceutical professionals in research, development, quality control, and manufacturing
• Regulatory authorities, laboratories, universities, and corporate libraries
• Global users who need UK/EU harmonised pharmaceutical standards